

GLAXOSMITHKLINE PLC  
Form 6-K  
February 21, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 2012

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--



Notification of Transactions of Directors and Persons Discharging Managerial Responsibility

I give below details of changes in the interests of Persons Discharging Managerial Responsibility (PDMRs), in the Ordinary shares of GlaxoSmithKline plc as a result of the sale of Ordinary shares at a price of £14.15 per share on 17 February 2012, to meet their tax liabilities following the vesting of awards granted in 2009 under the GlaxoSmithKline Share Value Plan:

| Name of PDMR | Number of shares sold | Number of shares retained |
|--------------|-----------------------|---------------------------|
| Mr P Thomson | 900                   | 830                       |
| Mrs V Whyte  | 900                   | 830                       |

The Company and PDMRs were advised of these transactions on 21 February 2012.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Company Secretary

21 February 2012

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 21, 2012

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc